NCT07316062
A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
Recruiting · Not specified · AstraZeneca · registry updated 2026-10-21
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.
Inclusion
- Stage I-III at initial NSCLC diagnosis
- Aged ≥18 years at first diagnosis of NSCLC
- Timeframe of NSCLC diagnosis:
- For DE1: diagnosed with NSCLC during the period between May 1st 2025 and December 31st 2025 For DE2: diagnosed with NSCLC during the period between May 1st 2026 and December 31st 2026 For DE3: diagnosed with NSCLC during the period between May 1st 2027 and December 31st 2027
Exclusion
- NSCLC is not the primary cancer diagnosis
- Patients with a recent history of other tumor or concurrent other tumor
- Patients participating in interventional clinical trials at time of initial diagnosis
- Patients with positive pregnancy status at the time of diagnosis